

Newport Beach and Birch Street

Clinical Research Treatment Trial Flowchart

AML NEWLY DIAGNOSED: NON-INTENSIVE

UCI 21-216

Gilteritinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy
FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar
Coord: S. Osorio
Accrual: 2/5

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs
Coord: K. McAbee
Accrual: 2/10

GASTRIC/GEJ: NEWLY DIAGNOSED METASTATIC

ECOG EA2183

(SOC + XRT)

PI: Hong
Coord: J. Koff
Accrual: 0/7

UCI 21-193

(FGFR inhibitor + mFOLFOX6 +
antiPD-L1 (nivolumab))

PI: Dayyani
Coord: M. Nguyen
Accrual: 1/12

GASTRIC/GEJ: NEOADJUVANT

UCI 21-191

(SOC therapy with ctDNA testing)

PI: Dayyani
Coord: A. Luna
Pending activation

NON-TREATMENT/BASIC SCIENCE

UCI 18-136

PI: Parajuli
Coord: B. Sanchez
Accrual: 72/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli
Coord: B. Sanchez
Accrual: 48/75

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

ADJUVANT

ALLIANCE A011801 (HER2+)

Antibody drug conjugate + kinase inhibitor

PI: Parajuli
Coord: Alexis Chavez
Accrual: 4/10

UCI 22-141 (TNBC)

PDL-1 inhibitor

PI: Parajuli
Coord: J. Miranda
Accrual: 1/5

1L METASTATIC

2L METASTATIC

3L METASTATIC

ETCTN 10546 (TNBC)

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)
 PI: Parajuli; Coord: A. Chavez
 Accrual: 1/5

UCI 19-145 (HR+/HER2-)

CDK 4/6 inhibitor + ER Regulator + Aromatase Inhibitor
 PI: Mehta; Coord: S. Ruiz, P. Cabanting
 Accrual: 16/20

UCI 21-212 (TNBC)

Antibody drug conjugate
 PI: Parajuli; Coord: S. Ruiz
 Accrual: 0/3

UCI 22-139 (HR+/HER2-)

PI3K/mTOR inhibitor
 PI: Parajuli; Coord: Alexis Chavez
 Accrual: 3/5

HCC: LOCOREGIONAL

UCI 19-49

Cabo + Ipi/Nivo + TACE

PI: Dayyani
Coord: Han Nguyen
Accrual: 19/35

HCC: 1-3L

UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani
Coord: H. Nguyen
Accrual: 7/10

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

PANCREATIC: BORDERLINE/LOCALLY ADVANCED

ETCTN 10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani
Coord: S. Duong
Accrual: 4/8

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 84/90

SARCOMA: RECURRENT

ETCTN 10556

Ipilimumab and Nivolumab +/- Cabozantinib

PI: Chow
Coord: B. Huynh
Accrual: 1/5

Neo-adjuvant or Adjuvant HNSCC

HN009

Cisplatin Q3 weeks vs Weekly
Locally Advanced HNSCC

Coord: E. Palmer-Torrison
Accrual: 0/5

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

KRAS

UCI 22-75

KRAS targeted Vaccine

PI: Valerin
Coord: M. Duron
Accrual: 5/7

CLDN18.2

UCI 21-10

Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani
Coord: K. Ghio
Accrual: 13/17